Skip to main content
. 2017 May 10;12(5):e0177184. doi: 10.1371/journal.pone.0177184

Table 1. The comparisons of baseline sociodemographic factors, life style behaviors, diabetes-related variables, drug-related variables and co-morbidity according to HbA1c-CV tertile groups in patients with type 2 diabetes enrolled in the National Diabetes Care Management Program, Taiwan (N = 27,257).

Variables HbA1c-CV (%)
Full cohort (N = 27,257) Propensity-score matched (N = 16,530)
≤8.4%
(n = 9,020)
8.4%-17.1%
(n = 9,005)
>17.1%
(n = 9,232)
≤8.4%
(n = 5,510)
8.4%-17.1%
(n = 5,510)
>17.1%
(n = 5,510)
Sociodemographic factors
 Gender
  Female 4934 (54.70) 4884 (54.24) 4691 (50.81) 2958 (53.68) 3012 (54.66) 2945 (53.45)
  Male 4086 (45.30) 4121 (45.76) 4541 (49.19) 2552 (46.32) 2498 (45.34) 2565 (46.55)
 Age (years) 60.93 (10.90) 60.77 (10.99) 59.54 (11.39) 60.32 (10.83) 60.81 (10.91) 59.98 (11.29)
Lifestyle behaviors
 Smoking 1253 (13.89) 1276 (14.17) 1626 (17.61) 843 (15.30) 775 (14.07) 879 (15.95)
 Alcohol drinking 708 (7.85) 780 (8.66) 890 (9.64) 477 (8.66) 462 (8.38) 496 (9.00)
Diabetes-related variables
 Duration of diabetes (years) 7.11 (8.16) 7.00 (7.10) 5.79 (6.90) 6.74 (6.45) 7.11 (6.92) 6.22 (7.00)
 Type of hypoglycemic drug use
  No medication 156 (1.73) 85 (0.94) 90 (0.97) 38 (0.69) 28 (0.51) 56 (1.02)
  One oral hypoglycemic drug 1958 (21.71) 1422 (15.79) 1373 (14.87) 770 (13.97) 719 (13.05) 889 (16.13)
  Two oral hypoglycemic drugs 3918 (43.44) 3794 (42.13) 3896 (42.20) 2454 (44.54) 2350 (42.65) 2357 (42.78)
  Three oral hypoglycemic drugs 1500 (16.63) 1728 (19.19) 1800 (19.50) 1098 (19.93) 1132 (20.54) 1044 (18.95)
  >3 oral hypoglycemic drugs 399 (4.42) 472 (5.24) 581 (6.29) 316 (5.74) 302 (5.48) 331 (6.01)
  Insulin 240 (2.66) 275 (3.05) 199 (2.16) 147 (2.67) 187 (3.39) 153 (2.78)
  Insulin+ oral hypoglycemic drug 849 (9.41) 1229 (13.65) 1293 (14.01) 687 (12.47) 792 (14.37) 680 (12.34)
Drug-related variables
 Hypertension drug treatment 3713 (41.16) 3457 (38.39) 3083 (33.39) 2016 (36.59) 2083 (37.80) 1966 (35.68)
 Glucocorticoids 142 (1.57) 136 (1.51) 154 (1.67) 85 (1.54) 81 (1.47) 88 (1.60)
Comorbidity
 Obesity 3354 (37.18) 3328 (36.96) 3196 (34.62) 1988 (36.08) 2049 (37.19) 1986 (36.04)
 CAD 737 (8.17) 751 (8.34) 625 (6.77) 411 (7.46) 461 (8.37) 384 (6.97)
 CHF 151 (1.67) 189 (2.10) 182 (1.97) 109 (1.98) 131 (2.38) 96 (1.74)
 Cancer 167 (1.85) 168 (1.87) 181 (1.96) 107 (1.94) 92 (1.67) 107 (1.94)
 Hyperlipidemia 2669 (29.59) 2444 (27.14) 2167 (23.47) 1437 (26.08) 1477 (26.81) 1405 (25.50)
 Hypertension 4187 (46.42) 4104 (45.57) 3651 (39.55) 2388 (43.34) 2519 (45.72) 2353 (42.70)
 Atrial fibrillation 35 (0.39) 37 (0.41) 35 (0.38) 17 (0.31) 24 (0.44) 18 (0.33)
 Chronic hepatitis 857 (9.50) 935 (10.38) 886 (9.60) 548 (9.95) 601 (10.91) 539 (9.78)
 Diabetic retinopathy 2015 (22.34) 2104 (23.36) 2089 (22.63) 1314 (23.85) 1308 (23.74) 1256 (22.79)
 Hypoglycemia 27 (0.30) 26 (0.29) 29 (0.31) 19 (0.34) 15 (0.27) 17 (0.31)
 Pneumonia 62 (0.69) 70 (0.78) 78 (0.84) 47 (0.85) 45 (0.82) 39 (0.71)
 Other diseases of the upper respiratory tract 92 (1.02) 75 (0.83) 78 (0.84) 48 (0.87) 50 (0.91) 50 (0.91)
 Acute respiratory infections 618 (6.85) 592 (6.57) 555 (6.01) 382 (6.93) 369 (6.7) 351 (6.37)
Blood biochemical measurement
 HbA1c (%) 7.59 (1.57) 7.96 (1.52) 8.39 (1.50) 8.09 (1.66) 8.06 (1.51) 8.12 (1.40)
 Fasting plasma glucose (mg/dL) 158.63 (46.26) 167.27 (46.18) 177.09 (50.66) 169.74 (50.63) 169.73 (46.18) 170.93 (48.74)
 FPG-CV (%) 24.42 (21.24) 29.31 (22.08) 41.64 (30.35) 31.79 (23.37) 31.21 (21.47) 33.57 (26.62)

Data were presented as counts (percentage) for categorical variables and mean (SD) for continuous variables.

SU: sulfonylurea; Met: metformin; Meg: meglitinide; Big: biguanide; TZD: thiazolidinedione; CAD: coronary artery disease; CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; FPG: fasting plasma glucose; FPG-CV: coefficient of variation of fasting plasma glucose; HbA1c-CV: coefficient of variation of HbA1c; SD: standard deviation.